Healthcare / BiotechnologyNasdaqCM
$50.70
-0.57 (-1.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-33.3M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$140M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-91.7%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-39.0M · FCF $-33.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | — | — | $4.9M | $10.1M | — | — | — | — |
| Net Income | $-39.0M | $-39.0M | $-53.0M | $-47.9M | $-46.2M | $-42.3M | $-29.5M | $-13.1M |
| EBITDA | $-38.9M | $-38.9M | $-52.7M | $-47.4M | $-45.7M | $-42.0M | $-29.4M | $-13.1M |
| EPS | -50.83 | -50.83 | -96.40 | -93.00 | -147.00 | -10181.25 | — | — |
| Operating Margin | — | — | -1143.4% | -515.3% | — | — | — | — |
| Net Margin | — | — | -1079.9% | -475.0% | — | — | — | — |
| Balance Sheet | ||||||||
| Debt/Equity | 0.02 | 0.02 | 0.10 | 0.06 | 0.09 | 0.04 | 0.01 | -0.10 |
| Current Ratio | 4.67 | 4.67 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-33.3M | $-33.3M | $-56.0M | $-33.3M | $-41.7M | $-36.0M | $-27.6M | $-12.6M |
| Returns | ||||||||
| ROE | -91.7% | -91.7% | -184.0% | -62.6% | -67.4% | -38.0% | -19.8% | 42.7% |
| Valuation | ||||||||
| P/B | 0.91 | 0.91 | 46.17 | 110.99 | 62.35 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | — | — | -51.3% | — | — | — | — | — |
| EPS Growth | 47.3% | 47.3% | -3.7% | 36.7% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-86.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-96.40 → -50.83
Residual
-86.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.